Posts Tagged ‘benefit/risk assessment’

Metformin in Diabetes and COVID-19: Boon or Bane?

December 19, 2020 — Metformin is one of those drugs that is older than dirt and still quite useful. It has helpful effects in obesity. It’s a mainstay of drug therapy for type 2 diabetes. But metformin presents a bit of a puzzle in patients with diabetes who become infected with COVID-19. Some signs point to a benefit for […]

FDA Requests Lorcaserin Withdrawal, Scant Disclosure

February 14, 2020 — FDA yesterday requested that Eisai withdraw lorcaserin (Belviq®) from the market due to a small increase in cancer observed in a large cardiovascular safety study. Eisai disagreed with the request but complied with the request nonetheless. We have no data to help us understand what is going on. Is FDA over-reacting to a spurious observation? […]

ObesityWeek: Can We Escape Nihilism in Childhood Obesity?

November 4, 2019 — With the opening of ObesityWeek today, we’ll see smart clinicians and scientists taking on tough questions right from the start. We have the privilege to moderate a panel discussion in the opening session. It’s a privilege because three researchers and clinicians will bring their best thinking and science to the dilemma of nihilism in childhood […]

Balancing the Safety and Effectiveness of Bariatric Surgeries

October 31, 2018 — Getting a handle on the real world effectiveness of any medical treatment is devilishly hard. For surgery, it’s even harder. Randomized controlled trials are not impossible, but almost. And many variables come into play that can cause big swings in effectiveness. That list starts with surgical skill and the quality of a program. And it […]